Research Paper Volume 15, Issue 19 pp 10453—10472
An immune signature to predict the prognosis of ATRX-wildtype glioma patients and guide immune checkpoint blockade therapy
Figure 10. Immunological characteristics of the three immune features. (A, B) Gene expression profiles of the high- and low-risk-score groups of ATRX-wt glioma tissues from TCGA were transformed into 22 immune cell expression matrices. (C) Immune cell differences between the high- and low-risk groups of ATRX-wt glioma tissues from TCGA. (D) Responders and non-responders to ICB treatment among ATRX-wt glioma patients in the high- and low-risk groups. *P < 0.05; **P < 0.01; ***P < 0.001.